Jazz Pharma, AbCellera strike antibody deal worth up to $876M

• AbCellera receives $56 million upfront for two programs starting within 12 months, plus $28 million tied to a third program, and is eligible for up to $792 million per program in option fees and milestone payments plus tiered royalties
• AbCellera will lead early-stage discovery using its antibody platform, while Jazz holds exclusive global rights to develop and commercialize resulting therapies
• T-cell engaging antibodies harness the immune system to direct T-cells to attack cancer cells, an approach increasingly explored for hard-to-treat tumors

Summary

Jazz Pharmaceuticals and Canadian biotech AbCellera have entered a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer treatment, with a total deal value of up to $876 million.

Financial Terms:

• AbCellera receives $56 million upfront for two initial programs launching within 12 months
• Additional $28 million tied to a potential third program
• Up to $792 million per program in option fees and milestone payments if Jazz advances candidates
• Tiered royalties on future product sales

Strategic Focus:

The partnership targets therapies for gastrointestinal cancers and other solid tumors, aligning with Jazz's strategy to expand its oncology portfolio beyond its core rare disease business. The collaboration may extend to include up to two additional programs.

Operational Structure:

• AbCellera leads early-stage discovery using its proprietary antibody development platform and may support later-stage development, including IND-enabling studies and clinical manufacturing
• Jazz Pharmaceuticals holds exclusive global rights to develop and commercialize resulting therapies upon exercising options

Technology Background:

T-cell engaging antibodies represent an emerging therapeutic approach that redirects the immune system's T-cells to attack cancer cells, showing particular promise for difficult-to-treat tumors.

Market Implications:

This deal strengthens Jazz's oncology pipeline while providing AbCellera with significant upfront capital and potential future revenue streams. The focus on solid tumors addresses a major unmet medical need in oncology, particularly as immunotherapy approaches expand beyond traditional applications.